Monoclonal antibodies: versatile platforms for cancer immunotherapy.
Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.
Weiner
Louis M
LM
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA. weinerl@georgetown.edu
Surana
Rishi
R
Wang
Shangzi
S
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D015703:Antigens, CD / Q000276:immunology; D019013:CD40 Antigens / Q000037:antagonists & inhibitors; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000627:therapeutic use; D003165:Complement System Proteins / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D019013:CD40 Antigens; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D003165:Complement System Proteins